Global POC Molecular Diagnostics Market Size By Type (Infectious Diseases, Oncology), By Application (Hospitals and Clinics, Research Institutes), By Region, And Segment Forecasts, 2023 to 2032

The Global POC (Point-of-Care) Molecular Diagnostics Market was valued at USD 4.9 billion in 2023 and is projected to surpass USD 12.8 billion by 2031, growing at a CAGR of 12.9% during the forecast period from 2023 to 2031. The market's expansion is driven by the increasing demand for rapid, accurate diagnostic solutions that can be deployed at the point of care, especially for infectious diseases, oncology, and genetic testing. As healthcare systems worldwide pivot towards decentralized testing models, POC molecular diagnostics are gaining traction for their ability to deliver fast results, improve patient management, and reduce hospital admissions.

Drivers:

Rising Prevalence of Infectious Diseases:

The global rise in infectious diseases such as COVID-19, influenza, tuberculosis, and sexually transmitted infections (STIs) is pushing healthcare providers to adopt fast and precise diagnostic tools. POC molecular diagnostics offer an effective solution by providing high sensitivity and specificity at the point of care.

Technological Advancements in Miniaturization:

Innovations in microfluidics, portable PCR systems, and integrated biosensors are enabling compact, easy-to-use devices that deliver lab-quality molecular results in near-patient settings. These advancements are accelerating market penetration across resource-limited environments.

Growing Demand for Decentralized Testing:

The shift towards decentralized healthcare delivery, particularly in rural and remote areas, is fueling the adoption of POC molecular diagnostics. They allow immediate clinical decisions, enhancing treatment outcomes and operational efficiency.

Restraints:

High Cost of POC Molecular Devices:

Despite the clinical advantages, high initial costs and the expense of consumables for molecular POC platforms can hinder adoption, particularly in developing countries and smaller clinics.

Regulatory and Reimbursement Challenges:

The market faces hurdles from complex regulatory pathways and limited reimbursement in several countries, which can delay commercialization and widespread adoption.

Opportunity:

Expansion into Emerging Markets:

Emerging economies in Asia-Pacific, Latin America, and Africa present untapped opportunities due to growing healthcare awareness, infrastructure development, and government initiatives promoting rapid diagnostic testing.

Integration with Digital Health and Telemedicine:

The integration of POC molecular diagnostics with telehealth platforms and electronic health records is opening new avenues for real-time data transmission, remote consultation, and disease surveillance, particularly during pandemics and outbreaks.

Market by System Type Insights:

Based on system type, the PCR-based systems segment held the largest market share in 2023. These platforms dominate due to their high accuracy, fast turnaround time, and versatility across a range of infectious diseases. Meanwhile, isothermal nucleic acid amplification systems are projected to witness the fastest growth due to their simplified operation and minimal equipment requirements, making them suitable for resource-constrained settings.

Market by End-use Insights:

Hospitals and clinics accounted for the largest end-use segment in 2023, benefitting from increasing demand for on-site rapid diagnostics to streamline clinical decision-making. However, homecare and decentralized settings are gaining momentum, particularly driven by the demand for self-testing kits and portable molecular systems for chronic disease monitoring and outbreak control.

Market by Regional Insights:

North America dominated the market in 2023, supported by advanced healthcare infrastructure, high investment in diagnostic technologies, and strong regulatory frameworks. However, Asia-Pacific is expected to exhibit the highest CAGR through 2031, fueled by a rising burden of infectious diseases, government healthcare initiatives, and increased accessibility to molecular testing platforms.

Competitive Scenario:

Key players in the global POC molecular diagnostics market include Abbott Laboratories, Roche Diagnostics, BioFire Diagnostics (bioMérieux), Cepheid (Danaher Corporation), QuidelOrtho Corporation, Thermo Fisher Scientific, Qiagen N.V., and HiberGene Diagnostics. These companies are actively engaging in partnerships, acquisitions, and new product launches to expand their market footprint. For example:

In 2023, Cepheid expanded its GeneXpert test menu with a new panel targeting multiple respiratory viruses.

Abbott introduced an upgraded version of its ID NOW platform, reducing result delivery time to under 10 minutes.

Roche announced the development of a mobile, cloud-connected molecular testing unit for emergency response teams.

Scope of Work – Global POC Molecular Diagnostics Market

Report Metric Details

Market Size (2023) USD 4.9 Billion

Projected Market Size (2031) USD 12.8 Billion

CAGR (2023–2031) 12.9%

Market Segments System Type (PCR, Isothermal, Others); End-use (Hospitals, Clinics, Homecare, Others); Region

Growth Drivers Infectious Disease Prevalence, Technological Innovation, Decentralized Testing Demand

Opportunities Emerging Markets, Digital Health Integration

Key Market Developments:

February 2024: Abbott received FDA EUA for its multiplex respiratory panel on the ID NOW platform, targeting COVID-19, flu, and RSV simultaneously.

October 2023: BioFire Diagnostics launched a next-generation POC system with improved portability and battery-operated functionality for field use.

June 2023: Qiagen partnered with a Southeast Asian government to implement its isothermal molecular tests in rural primary care clinics.

FAQs:

1) What is the current market size of the Global POC Molecular Diagnostics Market?

The market was valued at USD 4.9 billion in 2023.

2) What is the major growth driver of the Global POC Molecular Diagnostics Market?

The primary driver is the rising demand for rapid, accurate diagnostic tools for infectious diseases and decentralized healthcare.

3) Which is the largest region during the forecast period in the Global POC Molecular Diagnostics Market?

North America held the largest share in 2023, but Asia-Pacific is projected to grow at the fastest rate through 2031.

4) Which segment accounted for the largest market share in the Global POC Molecular Diagnostics Market?

PCR-based system type dominated the market in 2023.

5) Who are the key market players in the Global POC Molecular Diagnostics Market?

Key players include Abbott Laboratories, Roche Diagnostics, Cepheid, BioFire Diagnostics, and Thermo Fisher Scientific.